

# SMOORE INTERNATIONAL HOLDINGS LIMITED 思摩尔国际控股有限公司

(于开曼群岛注册成立的有限公司) (Incorporated the Cayman islands with limited liability) 股份代号Stock Code: 6969

# 2024年中期业绩发布会

2024 INTERIM RESULTS ANNOUNCEMENT


### **Disclaimer**

The information contained in this document is for general informational purposes only and does not constitute an offer, solicitation, invitation or recommendation to subscribe for or purchase any securities, or other products or to provide any investment advice or service of any kind. This document is solely intended for distribution to and use by professional investors. This document is not directed at, and is not intended for distribution to or use by, any person in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Smoore International Holdings Limited ("Smoore") to any registration requirement within such jurisdiction or country.

This document contains forward-looking statements which are based on the current expectations, estimates, projections, beliefs and assumptions of Smoore about the businesses and the markets in which it and its subsidiaries operate. These forward-looking statements are not guarantees of future performance and are subject to market risk, uncertainties and factors beyond the control of Smoore. Therefore, actual outcomes and returns may differ materially from the assumptions made and the statements contained in this document.

Although the information contained in this document is obtained or compiled from sources believed to be reliable, Smoore does not guarantee the accuracy, validity, timeliness or completeness of the information or data for any particular purpose, and shall not accept any responsibility for, or be liable for, errors, omissions or other inaccuracies in the information or for the consequences thereof. The information set out in this document is provided on an "as is" and "as available" basis and may be amended or changed. It is not a substitute for professional advice which takes account of your specific circumstances and nothing in this document constitutes legal advice. Smoore shall not be responsible or liable for any loss or damage, directly or indirectly, arising from the use of or reliance upon any information provided in this document.

# Contents






# **Key Financials of 2024 Interim Results**

RMB: Million	2024 H1	2023 H1	Changes
Revenue	5,037.2	5,122.9	-1.7%
Gross profit	1,914.6	1,855.4	+3.2%
- Gross margin (%)	38.0%	36.2%	+1.8 pp
Distribution and selling expenses	374.5	208.7	+79.5%
- % of total revenue	7.4%	4.1%	+3.3 pp
Administrative expenses	339.2	465.9	-27.2%
- % of total revenue	6.7%	9.1%	-2.4 pp
R&D expenses	760.1	614.7	+23.7%
- % of total revenue	15.1%	12.0%	+3.1 pp
Profit before tax	811.6	796.2	1.9%
- % of total revenue	16.1%	15.5%	+0.6pp
Net profit	683.2	717.3	-4.8%
Earnings per share (RMB cents)	11.2	11.8	-5.1%
Dividend per share (HK\$ cents)	5.0	5.0	-

02 **Business Overview** 

### **Dedicated to Building the World's Leading Atomization Technology Platform**

With atomization technology at the core, adhering to "leading in technology and manufacturing, atomization-focused diversification and technology branding"





#### **Overview of 2024 Interim Results**

# Self-branded Business (APV)

Revenue RMB 1.12Bn

+71.9% yoy



- Revenue of RMB 929mn, +88.0% yoy
- Directly reaching the end-consumer market, comprehensively promoting digital management



**U.S.** Market

- Revenue of RMB 187mn, +20.6% yoy
- Increase marketing and promotion, market expansion, and strengthen the construction of terminal channels

# **Corporate Client Business (ODM)**

Revenue RMB 3.92Bn

-12.3% yoy



#### **European and Other Markets**

- Revenue of RMB 1.98Bn, -16.0% yoy
- The regulatory framework is gradually improving, and the needs of end-consumers are shifting towards compliant products
- Q2 revenue of pod-based products +93.2% qoq, +22.5% yoy



- Revenue of RMB 1.86Bn , -9.8% yoy
- The market for compliant products is gradually recovering, and the market share of major customers is ranked first
- Q2 revenue of pod-based products, +6.1% qoq, +6.5% yoy



#### **China Market**

Revenue of RMB 88mn, +41.4% yoy



#### **Self-branded Business Sales**

Digitalization drives the leading technology and products



The iterative version of the XROS mouth-to-lung product is highly popular among consumers

Localized sales team
Strengthen international market expansion



**Global Leading Brand of Open-system Products** 



Revenue RMB1.12Bn +71.9% yoy



Channel penetration to improve terminal coverage



Revenue of European and other markets +88.0% yoy



Revenue of U.S. market +20.6% yoy

Strengthen market insights
Cater to consumer taste demands




# Disposable Products

Pod-based Products

## Corporate Client Business (ODM) - European and Other Markets

The regulatory framework is gradually changing, and the demand for traditional disposable electronic vaping products is shifting towards new closed-system and open-system products







## Corporate Client Business (ODM) - European and Other Markets

Launched multiple series of compliant new products in collaboration with customers, gaining recognition from both customers and end users



User experience comprehensively upgraded
Rapidly meeting market demand
Revenue from pod-based products

+ 93.2% qoq, +22.5% yoy in Q2



FEELM Pro, the next-generation pod-based product solution

Aerosol particle size increase of 35%

Taste consistency improved to 95%



Birmingham electronic vaping exhibition



Awarded two major prizes - "Best Manufacturer" and "Vapouround Hall of Fame"



World vape show in Dubai

### **Corporate Client Business (ODM)** – U.S. Market

Increase of law enforcement, revenue from pod-based products increased by 6.5% yoy and 6.1% qoq in Q2, and the U.S. market is expected to recover

Various states advancing electronic vaping registry bills



35 states have introduced electronic vaping registry bills, with 10 states having passed them

Deepening strategic customer relationships



Helped a major customer maintain its No. 1 market share in the US through measures such as improving the level of production automation and optimizing the cost structure<sup>1</sup>

FDA approved menthol-flavored products



FDA approved the first mentholflavored products



FDA strengthened law enforcement, with an increase in the number of enforcement cases<sup>2</sup>

Note 1: Data from BAT's interim report and Nielsen

Note 2: Data from FDA website https://timp-ccid.fda.gov/



# Inhalation Therapy: Steady Advancement of Project Progress and Building a Flexible Model






- Continually developing drug-device combination products for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD)
- Completed the development and production layout of several devices for asthma and COPD, and developed over 10 drug formulations
- Research achievements have been recognized by the industry

Collaborative R&D with Pharmaceutical Industry Clients, Sharing R&D Achievements













# 

# **Exploring Beauty Beyond Health**

MOYAL brand pioneered the global TPS transdermal technology to help people with problematic and sensitive skin solve effective skincare challenges, finding more efficient and safer skincare solutions.



### March 10

MOYAL made its official debut at the 63rd China (Guangzhou) International Beauty Expo.



## July 5 - 10


#### MOYAL launched the "Brand Friends - Ulanqab Hiking Trip"

A MOYAL Skincare Supply Station was set up at the hiking site to provide MOYAL's fans with skincare knowledge in harsh environments and to experience the immediate nourishing effect of the MOYAL atomization beauty products.



# **Self-branded Business (APV)**

#### Revenue from APV was RMB1.12bn, increased 71.9% yoy



#### **European and Other Markets**

- Revenue was RMB929 million, increased 88.0% yoy
- Accurate consumer insights and continuous promotion of localization
- Localized operation system and digital management system
- Demand for traditional disposable products is shifting towards open-system and podbased products

#### **U.S. Market**

- Revenue was RMB187 million, increased 20.6% yoy
- Replicating the successful experience in Europe and vigorously expanding the U.S.
   market
- Actively promoting the localization of insights, R&D, and sales systems

## **Corporate Client Business (ODM)**

Revenue from ODM was RMB3.92bn, decreased 12.3% yoy



#### **European and Other Markets**

- Revenue was RMB1.98bn, decreased 16.0% yoy
- Regulation is gradually strengthening, and demand for traditional disposable products is shifting towards new closed-system and open-system products
- Revenue from pod-based products has been improving quarter-over-quarter and increased notably by 93.2% qoq and 22.5% yoy in Q2

#### **U.S.** Market

- Revenue was RMB1.86bn, decreased 9.8% yoy
- The regulatory framework is becoming clearer, and enforcement is strengthening
- Helping major client maintain its No.1 ranking market share
- In Q2, pod-based product revenue increased by 6.5% yoy and 6.1% qoq

#### **China Market**

• Revenue was RMB88mn, increased **41.4%** yoy.

## **Product Structure Changes and Cost Efficiency Enhance Profitability**

#### **Gross Profit and Gross Profit Margin**

#### RMB Million




#### Gross profit margin increased to 38.0%

- The self-branded business with higher gross profit margins
   has seen significant growth, increasing its share of revenue
- Reducing costs through Amoeba management

#### **Profit before tax and Pre-tax Profit Margin**

#### **RMB Million**




#### Pre-tax profit margin increased to **16.1%**

 The increase in gross profit margin, growth in other income, and significant reduction in administrative expenses have led to an improvement in pre-tax profit margin

## Improving Operational Efficiency, Actively Expanding International Markets


#### **Selling Expenses**



#### Selling expenses +79.5% yoy to RMB375 million

- Continuously improving global localization capabilities, building localized teams
- Increasing efforts to expand international markets and promote new products


#### **Administrative Expenses**



#### Administrative expenses -27.2% yoy to RMB339 million

 Continuously implementing the Amoeba management, strengthening budgeting management, and improving operational efficiency

# Improving R&D Efficiency with Increased Investment in the field of Inhalation Therapy




	RMB Million				
		24H1	23H1	Change	
	Electronic Nicotine Delivery (including electronic vaping and HNB products)	482	419	15.1%	
	Atomization Products for Special Purpose	93	82	12.5%	
	Inhalation Therapy and Beauty Atomization	185	114	63.2%	
	Total	760	615	23.7%	

R&D expenses were RMB760mn, +23.7% yoy

The main growth in investment came from the inhalation therapy and HNB products



# Comprehensively Building Atomization Technology Industry Ecosystem Grounded in Science and Technology





For more information about the Company,
please follow our WeChat public account
"思摩尔科技" and "思摩尔国际投资者关系"

Investor Relations Contact ir@smooreholdings.com

**Investor Relations Consultants** 

smoore@christensencomms.com



Atomization Makes Life Bette